TY - JOUR T1 - Dr. LeBlanc, <em>et al</em> reply JF - The Journal of Rheumatology JO - J Rheumatol SP - 339 LP - 339 DO - 10.3899/jrheum.121413 VL - 40 IS - 3 AU - CLAIRE M.A. LEBLANC AU - BIANCA LANG AU - LORI B. TUCKER Y1 - 2013/03/01 UR - http://www.jrheum.org/content/40/3/339.1.abstract N2 - To the Editor:We thank Dr. Cohen and colleagues for their interest1 in our article2 describing inequities in access to biologic treatments for juvenile idiopathic arthritis (JIA) in Canada. We agree with their comments regarding challenges in treating children with relatively rare diseases such as JIA under provincial-based drug funding programs. Unfortunately, as we have described in our article, access to treatment for children with JIA currently depends on where they live in Canada.Dr. Cohen and colleagues refer to a number of misconceptions in our article that we would like to clarify. We appreciate their description of the collaborative … Address correspondence to Dr. LeBlanc, McGill University – Pediatrics, 2300 Rue Tupper, Room C504, Montreal, Quebec H3H 1P3, Canada; E-mail: claire.leblanc4{at}gmail.com ER -